TP53 and acute lymphoblastic leukemia: Idasanutlin and negative control UNC0321 had no effect on p53 signaling in ALL-PO, which is in concordance with the dose–response curves for Idasanutlin and UNC0321 to which ALL-PO cells are completely resistant (Figure 2B).